Skip to content
Adam Torkildson – Lifestyle
Author:
Kymera Therapeutics, Inc.
Kymera Therapeutics Appoints Penny Carlson as Senior Vice President, Development Operations
June 8, 2026
Kymera Therapeutics Presents New Preclinical Lupus Data for KT-579, First-in-Class, Oral IRF5 Degrader, at EULAR and FOCIS Congresses
June 8, 2026
Kymera Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference
May 27, 2026
Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses
May 15, 2026
Kymera Therapeutics to Participate in Upcoming May Investor Conferences
May 6, 2026
Kymera Therapeutics Presents New Preclinical IBD Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at Digestive Disease Week
May 5, 2026
Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update
April 30, 2026
Kymera Therapeutics to Report First Quarter 2026 Financial Results on April 30, 2026
April 23, 2026
Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe Asthma
April 13, 2026
Kymera Therapeutics Announces Gilead Sciences’ Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development Candidate
April 9, 2026
1
2
Next Page
→